Sacituzumab govitecan
Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Wikipage redirect
Link from a Wikipage to another Wikipage
primaryTopic
Sacituzumab govitecan
Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
has abstract
Sacituzumab govitecan, sold un ...... e a first-in-class medication.
@en
alternative name
Trodelvy
@en
CAS number
1491917-83-9
DrugBank
FDA UNII code
M9BYU8XDQ6
KEGG
MedlinePlus
PubChem
Link from a Wikipage to an external page
Wikipage page ID
47,556,310
page length (characters) of wiki page
Wikipage revision ID
1,023,578,174
Link from a Wikipage to another Wikipage
ATC prefix
None
@en
CAS number
ChemSpiderID
none
@en
DailyMedID
Sacituzumab_govitecan
@en
DrugBank
DB12893
@en
KEGG
D10985
@en
legal US
Rx-only
@en
mab type
mab
@en
MedlinePlus
a620034
@en
pregnancy category
Contraindicated
@en
PubChem
91,668,186
routes of administration
SMILES
CCC1=C2CN3CC2=NC9=C1C=CO
@en
source
zu/o
@en
StdInChIKey
ULRUOUDIQPERIJ-PQURJYPBSA-N
@en
synonyms
IMMU-132, hRS7-SN-38, sacituzumab govitecan-hziy
@en
target
tradename
Trodelvy
@en
type
mab
@en
UNII
M9BYU8XDQ6
@en
wikiPageUsesTemplate
subject
hypernym
comment
Sacituzumab govitecan, sold un ...... e a first-in-class medication.
@en
label
Sacituzumab govitecan
@en